Login
Companies $ITGR
$126.97 +$0.00 (0.0%) After hours
Integer Holdings Corp logo

Integer Holdings Corp

integer.net

What Do They Do?

Designs, develops and manufactures components, assemblies and finished medical devices for medical device makers, including cardiovascular, heart-rhythm and neuromodulation products.

How Do They Make Money?

Integer sells medical products, with most sales counted when goods ship; certain products with no other use are counted as work progresses when the contract allows payment for completed work. Standard payment terms range from 30 to 90 days.

revenue
SegmentShareRevenue
Cardio And Vascular
Sold outright

60%
FY2022: 53%
Cardiac Rhythm Management & Neuromodulation
Sold outright

36%
FY2022: 40%
Other Markets
Sold outright
4.2%
FY2022: 7.3%

Who Are Their Customers?

Large multinational medical-device makers and their affiliated subsidiaries are the main buyers; Integer sells directly to them, with limited exceptions.

Customers above 10% of revenue, FY2025
of revenue from three customers (20%, 15%, 14%)
FY2023: 46% from three customers

Do Revenues Turn Into Profits?

Yes. It kept 6 cents of every revenue dollar as net income in FY2025 and turned 6 cents into free cash flow.

Operating income, FY2025
12% of revenue
▲ +6% vs FY2024 ($208.2M, 12%)
Net income, FY2025
6% of revenue
▼ −14% vs FY2024 ($119.9M, 7%)
Free cash flow, FY2025
6% of revenue
▲ +5% vs FY2024 ($99.8M, 6%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Oct 2, 2026
Revenue
▼ −4%
vs $467.7M in Q3 FY2025
Net income
▼ −62%
vs $39.7M in Q3 FY2025
Cardio & Vascular share of revenue vs 59.3% in Q3 FY2025
  • Aug 4, 2026 Signed a merger agreement with a KKR affiliate Stockholders are to receive $127 per share in cash; closing remains subject to stockholder and regulatory approvals.
  • Aug 3, 2026 Withdrew previously issued financial outlook Integer also said it would not host its scheduled earnings call.

Growing. Revenue grew 52% in 4 years, from $1.2B in FY2021 to $1.9B in FY2025, about 11% a year.

Moved away from non-medical batteries The older report described a separate non-medical battery business serving energy, military and environmental markets. The latest report describes a medical-technology focus and says Integer sold Electrochem, which served nonmedical applications.

Portable medical sales are being wound down The older report presented rechargeable batteries and chargers for medical devices as part of a product line. The latest says sales are being transitioned to other suppliers ahead of a planned market exit.

Revenue over time
Cardio And Vascular Cardiac Rhythm Management & Neuromodulation Other Markets
$2B$1B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support